The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis

Table 2

Characteristics of studies included in this meta-analysis.

Study	Country	Phase	Trial name	Treatments		No. of patients		Age (years)		Median PSA (ng) (ml)
				Test	Control	Test	Control	Test	Control	Test	Control
James [15]	International	III	STAMPEDE	ABI + PRE + ADT	Placebos + ADT	960	957	67 (42–85)	67 (39–84)	51 (0–21460)	56 (0–10530)
Fizazi [16]	International	III	LATITUDE	ABI + PRE + ADT	Placebos + ADT	597	602	67.3 ± 8.5	66.8 ± 8.7	NR	NR
Chi [17]	International	III	TITAN	APA + ADT	Placebos + ADT	525	527	69 (45–94)	68 (43–90)	5.97 (0–2682)	4.02 (0–2229)
Armstrong [18]	International	III	ARCHES	ENZ + ADT	Placebos + ADT	574	576	70 (46–92)	70 (42–92)	5.4 (0–4823.5)	5.1 (0–19000.0)
Davis [20]	International	III	ENZAMET	ENZ + ADT	ADT	563	562	68.9 ± 8.1	68.8 ± 8.3	NR	NR
Smith [19]	International	III	ARASENS	DAR + DOC + ADT	Placebos + DOC + ADT	651	654	67 (41–89)	67 (42–86)	30.3 (0–9219)	24.2 (0–11947)

PSA, prostate-specific antigen; ABI, abiraterone; PRE, prednisolone; ADT, androgen-deprivation therapy; ENZ, enzalutamide; APA, apalutamide; DAR, darolutamide; DOC, docetaxel; NR, not reported. The symbol indicates that the data were presented as the median (range) or mean ± standard deviation.